Biovie Inc Stock Price, News & Analysis

BioVie Inc (NASDAQ: BIVI) announced the pricing of a registered direct offering of 2,667,000 shares of common stock at $2.25 per share, raising gross proceeds of $6,000,750. The company will also issue unregistered warrants to purchase up to 2,667,000 shares in a concurrent private placement, with an exercise price of $2.12 per share. The warrants will be exercisable after six months and expire five years after the initial exercise date. The proceeds will be used for working capital and general corporate purposes. ThinkEquity is serving as the sole placement agent, with the offering expected to close around October 24, 2024.

BioVie Inc. (Nasdaq: BIVI) has announced the closing of its previously announced registered direct offering and concurrent private placement. The company sold 4,443,000 shares of common stock at $1.50 per share in a registered direct offering. Additionally, in a private placement, BioVie issued unregistered warrants to purchase up to 4,443,000 shares of common stock at an exercise price of $1.37 per share.

The gross proceeds from the offering amount to $6,664,500. BioVie intends to use the net proceeds primarily for working capital and general corporate purposes. ThinkEquity acted as the sole placement agent for the offering. The common stock was offered through a shelf registration statement, while the warrants were issued in a private placement under exemptions from registration.

BioVie Inc. (NASDAQ: BIVI) has announced the pricing of a registered direct offering of 4,443,000 shares of common stock at $1.50 per share, raising gross proceeds of $6,664,500. The company is also issuing unregistered warrants to purchase up to 4,443,000 shares in a concurrent private placement. These warrants have an exercise price of $1.37 per share, will be exercisable after six months, and expire five years from the initial exercise date.

The offering is expected to close around October 22, 2024. BioVie plans to use the net proceeds for working capital and general corporate purposes. ThinkEquity is acting as the sole placement agent for this offering, which is being conducted under a shelf registration statement filed with the SEC.

BioVie Inc. (NASDAQ: BIVI) has received a Notice of Allowance from the Japan Patent Office for its novel liquid formulation of terlipressin acetate. This formulation, which is stable at room temperature for up to 24 months, can be packaged in a pre-filled syringe, offering significant advantages for treating patients with cirrhosis and ascites, particularly in home-care settings.

The company has now secured patents for this formulation in the United States, India, Japan, and Chile, with pending applications in eight additional markets. This development strengthens BioVie's intellectual property protection and enhances the value of its BIV201 program, which aims to provide a more patient-centric ambulatory treatment for ascites and hepatic failure.

Terlipressin is currently used in over 40 countries to treat complications of liver cirrhosis, but the recent US approval is for a lyophilized powder form requiring reconstitution and refrigeration. BioVie's liquid formulation offers improved convenience and safety, potentially benefiting patients with cirrhosis and ascites, who currently face treatment options and poor survival rates.

RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Genetic Technologies on Bloomberg TV this Saturday, October 12, at 7 p.m. ET. The interviews will feature:

1. Cuong Do, President and CEO of BioVie, discussing the company's late-stage clinical programs for neurodegeneration and liver disease. Key points include:

• Bezisterim's ability to modulate TNFα production, leading to clinical improvements
• Planned Phase 2b trial for Parkinson's in late 2024
• Upcoming Phase 3 trial for Alzheimer's in late 2025
• Ongoing partnering discussions for bezisterim's geographic rights
• Plans for an ascites Phase 3 trial

2. Peter Rubinstein, Executive Chairman of Genetic Technologies, providing a corporate update on:

• EasyDNA platform with $7 million in annual recurring revenues
• Expanding product portfolio with over 50 risk assessment tests
• B2B commercialization strategy for geneType multi-risk test
• Focus on direct-to-consumer testing programs
• Recent corporate restructure to reduce cash burn

BioVie Inc. (NASDAQ: BIVI) has received a Notice of Allowance from the USPTO for a patent application covering a novel liquid formulation of terlipressin acetate. This formulation demonstrates room-temperature stability for up to 24 months and can be packaged in a pre-filled syringe. The patent is expected to be listed in the Orange Book and supports BioVie's development of a more patient-centric ambulatory treatment for patients with ascites and hepatic failure.

The liquid formulation offers significant advantages over the recently approved lyophilized powder form of terlipressin in the US, which requires reconstitution and refrigerated storage. BioVie's formulation could improve dosing convenience and safety, particularly in home-care settings. The company has also secured patents for this formulation in India and Chile, with applications pending in nine additional markets.

BioVie Inc. (Nasdaq: BIVI), a clinical-stage company developing therapies for liver disease and neurological disorders, has closed its previously announced public offering. The offering included 1,360,800 shares of common stock, 600,000 pre-funded warrants, and warrants to purchase up to 1,960,800 shares at a combined price of $1.53 per share or pre-funded warrant with associated common warrant. The common warrants have an exercise price of $1.53 and are exercisable for five years. The offering raised approximately $3,000,000 in gross proceeds. BioVie plans to use the net proceeds for working capital and general corporate purposes. ThinkEquity acted as the sole placement agent for this best efforts offering, which was conducted under a shelf registration statement filed with the SEC.

BioVie Inc. (NASDAQ: BIVI), a clinical-stage company developing drug therapies for liver disease and neurological disorders, has announced the pricing of a public offering. The offering includes 1,960,800 shares of common stock (or pre-funded warrants) and warrants to purchase up to 1,960,800 shares at a combined price of $1.53 per share and associated warrant. The warrants have an exercise price of $1.53 and will be exercisable for five years upon issuance.

The company expects to raise approximately $3,000,000 in gross proceeds, which will be used primarily for working capital and general corporate purposes. The offering is set to close on September 25, 2024, subject to customary closing conditions. ThinkEquity is acting as the sole placement agent for this best efforts public offering.

BioVie Inc. (NASDAQ: BIVI), a clinical-stage company focused on developing innovative drug therapies for advanced liver disease and neurological disorders, has announced its intention to conduct a public offering of common stock shares and accompanying purchase warrants. The company may also offer pre-funded warrants in lieu of common stock. ThinkEquity is acting as the sole placement agent for this best efforts offering.

The offering's proceeds are intended primarily for working capital and general corporate purposes. The securities will be offered under a shelf registration statement filed with the SEC. A preliminary prospectus supplement and accompanying prospectus will be available from ThinkEquity and the SEC's website. The offering's completion is subject to market conditions, with no guarantees regarding its execution or terms.